Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
September 01 2016 - 9:10AM
Business Wire
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical
company developing treatments to make a difference in the lives of
patients with neurological and psychiatric disorders, today
announced it will be featured as a presenting company at the 23rd
Annual NewsMakers in the Biotech Industry Conference. The
conference is being held on September 9, 2016, at the Millennium
Broadway Hotel in New York City.
Dr. Uli Hacksell, President and Chief Executive Officer of
Cerecor, will provide an overview of the Company’s business during
a live presentation at 9:30 a.m. (Eastern Time) and will be
available to participate in one-on-one meetings with investors who
are registered to attend the conference.
About CerecorCerecor is a clinical-stage
biopharmaceutical company developing innovative drug candidates to
make a difference in the lives of patients with neurological and
psychiatric disorders. We are committed to the development of drugs
that improve lives by applying our extensive knowledge and
experience in central nervous system
disorders. Cerecor is currently pursuing the development
of two clinical Phase 2-stage product candidates: CERC-301 and
CERC-501.
CERC-301 is an oral, NR2B specific N-methyl-D-aspartate (NMDA)
receptor antagonist that is currently in a Phase 2 clinical
trial as an oral, rapidly acting adjunctive treatment for patients
with severe major depressive disorder (MDD) who are failing to
achieve an adequate response to their current antidepressant
treatment, with a rapid onset of effect. We expect top-line data
from this trial in the first half of 2017. Cerecor received fast
track designation by the United States Food and Drug Administration
in November 2013 for CERC-301 for the treatment of MDD. We believe
CERC-301 has the potential to be a first-in-class medication that
may significantly reduce depressive symptoms in a matter of
days.
CERC-501 is a potent and selective kappa opioid receptor (KOR)
antagonist that is currently in a Phase 2 clinical trial for
smoking cessation that is expected to provide top-line data in
December 2016. In addition to Cerecor’s Phase 2 trial, three
externally-funded clinical trials are being conducted to evaluate
the use of CERC-501 in treating depressive symptoms, stress related
smoking relapse and cocaine addiction. One study is being conducted
under the auspices of the National Institute of Mental Health, the
second is collaboration between Cerecor and Yale investigators with
National Institutes of Health funding and the third study is being
conducted at Rockefeller University Hospital and is funded by a
private foundation.
Cerecor has one preclinical stage asset, CERC-406, a brain
penetrant catechol-O-methyltransferase (COMT) inhibitor with
potential procognitive activity.
For more information about the Company and its products, please
visit www.cerecor.com or contact Mariam E. Morris,
Chief Financial Officer, at (443) 304-8002.
Forward-Looking StatementsThis press release may include
forward-looking statements made pursuant to the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts. Such forward-looking
statements are subject to significant risks and uncertainties that
are subject to change based on various factors (many of which are
beyond Cerecor’s control), which could cause actual results to
differ from the forward-looking statements. Such statements may
include, without limitation, statements with respect to Cerecor’s
plans, objectives, projections, expectations and intentions and
other statements identified by words such as “projects,” “may,”
“will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,”
“predicts,” “believes,” “expects,” “anticipates,” “estimates,”
“intends,” “plans,” “potential” or similar expressions (including
their use in the negative), or by discussions of future matters
such as the development of product candidates or products,
technology enhancements, possible changes in legislation, and other
statements that are not historical. These statements are based upon
the current beliefs and expectations of Cerecor’s management but
are subject to significant risks and uncertainties, including those
detailed in Cerecor’s filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the
forward-looking statements. Except as required by applicable
law, Cerecor expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Cerecor’s expectations with respect thereto or any change in
events, conditions or circumstances on which any statement is
based.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160901005200/en/
MacDougall Biomedical CommunicationsDoug MacDougall or Joe
Rayne, 781-235-3060ir@cerecor.com
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cerecor (NASDAQ:CERC)
Historical Stock Chart
From Jul 2023 to Jul 2024